Research Studies

The Eynsham Medical Group is a research active practice and is part of the Thames Valley and South Midlands Clinical Research Network (National Institute for Health Research).

We actively enrol patients into studies looking for ways to improve health and treatments. Dr Ian Binnian acts as Principal Investigator, and practice nurses Leanda Rankin and Janice Williams are our specialist research nurses.

We work with academic and commercial institutions (such as Oxford, Southampton and Keele universities, and Abbott Ltd pharmaceutical company) for medical research purposes.

Your consent will be sought before enrolment in any study; however, if you never wish your data to be used for the purpose of research you may opt out either by clicking on the following link https://www.nhs.uk/your-nhs-data-matters/manage-your-choice/ or by contacting the NHS Digital Contact Centre on 0300 303 5678.

Sometimes we are asked for disease-based information for research purposes, and anonymised/pseudo-anonymised population data is requested. We contribute anonymised data to CPRD (Clinical Practice Research Datalink) for public health research. Individual patients cannot be identified from this information, and we would not seek an individual’s consent for these purposes.  Pseudo-anonymised data is provided to IQVIA for medication and disease pattern research; however, if you have chosen to opt out of your data being used for research through the National Data Opt Out, your choice will be respected and your data will not be used for research.

https://www.cprd.com/safeguarding-data

https://www.iqvia.com/about-us/privacy/gdpr-at-iqvia

If you would like to take part in any of our studies or find out more about them please book a telephone consultation with one of our research nurses, Janice Williams or Leanda Rankin.

We are currently taking part in the following studies:

BEST3 Trial

More than 11,500 patients across 10 regions of England have been recruited into this trial into the early cancer detection/prevention.

Trial Newsletter – Issue 7

Toast Study

What are we hoping to find out?

Does using a single dose of oral steroid medication reduce the length and severity of people suffering from an acute sore throat?

Who is suitable?

Anyone aged 18 years and over who presents to their GP with a sore throat and painful swallowing which has been of less than 1 week duration.

What does it involve?

Some screening questions from the GP or research nurse at your GP practice followed by a throat swab and single capsule of medication. The medication may be a steroid medicine or placebo.

BARACK-D study

What are we hoping to find out?

Whether people with moderate level kidney impairment benefit from a medication called spironolactone taken over a 3 year period

Who is suitable?

Anyone aged 18 years and over with a moderate level of Chronic Kidney Disease defined by results from 2 blood tests in the last year.

What does it involve?

Seeing a GP/research nurse at the surgery and completing baseline blood tests and blood pressure along with a few questions. Follow up over the next 3 years with visits to the research nurse for further blood test and blood pressure monitoring.

OASC Study

What are we hoping to find out?

Whether using a course of oral steroid medication will reduce the length and severity of people suffering from an acute chest infection.

Who is suitable?

Anyone aged 18 years and over who presents to their GP with chest infection symptoms of less than 1 month’s duration.

What does it involve?

Some screening questions from the GP or research nurse at your GP  practice, following which your doctor will randomise you via the research trial computer to receive a 5 day course of oral steroid or a 5 day course of placebo medication [both doctor and patient aren’t aware of what they receive]. You will need to complete a daily diary.

Completed Studies

The Montelukast for Post-Infectious Cough in Adults (MAC) Trial

We are delighted to let you know that the findings of the MAC trial have been published online in The Lancet Respiratory Medicine:

http://www.thelancet.com/journals/lanres/article/PIIS2213-2600%2813%2970245-5/abstract

276 patients were recruited into this trial, of whom 70 (25%) had whooping cough. Montelukast is not an effective treatment for post-infectious persistent cough; however, the good news is that in around half of patients the cough will almost completely settle two weeks after initial presentation in primary care. Thank you to everyone who took part in this study.

Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults With Acute Lower Respiratory Tract Infection 
A Randomized Clinical Trial

View information on the clinical trial

Other Completed Studies

The following studies have now finished recruiting patients: CAPS (The Children and Persistent Cough Study), AIRS (A Study of Auto inflation for schoolchildren with glue ear). Thank you to everyone who took part. The results of the trial are available at http://www.phc.ox.ac.uk/

Research for Patients

The RSC works closely with the RCGP patients group. Patients are encouraged to join this group and feedback to the centre.

What is the RSC National Monitoring Network?

The National Monitoring Network is a network of GP surgeries across England that contributes medical information to an electronic database. The information collected by the network is used for the surveillance of a range of common infections and diseases that doctors regularly diagnose. The current focus is on spotting changes in infections and other diseases. It also researches vaccine benefits. It is involved in other research, including diabetes, though any research will be ethically approved by the relevant research ethics committee. The network is mainly funded by Public Health England.

Why is this network important?

The network is monitoring infections and diseases in the community. Surveillance is also important for responding to specific incidents that might affect the health of the public. For example, the RSC can monitor influenza rates during the winter. If these exceed normal levels, we inform doctors and hospitals to warn them that they might expect an increase in patients using services. A high level of influenza can also trigger the release of special additional measures, such as the release of anti-flu medications. During the pandemic of 2009, the RSC provided samples to observe the spread of the virus in the community and monitor if the anti-viral drugs prescribed were effective.

How is information from each consultation used?

After a consultation, the doctor enters the information using relevant codes in the patient’s computerised medical record system. This information includes the GP’s diagnosis of what might be causing the patient’s symptoms or illnesses. The RSC performs a search on the surgery computer system data for information about all new diagnoses that have been made. These diagnoses include information about diseases, and information about other activities in the surgery such as vaccination details, so that the RSC can study effectiveness. The data are anonymised prior to being used for research. As the identifying information (such as names, addresses and date of birth) are removed from the record, patients cannot be identified from these extracted records.

How does this affect patients?

All information is collected anonymously and should not affect patient care in any way. The information is extremely important for protecting the whole population. The RSC has taken all measures necessary to ensure that patient confidentiality is maintained. There is a mechanism by which a patient can decide not to allow their information to be used: please inform your GP and your information will not be included in the anonymised database.

Useful links

Join Dementia Research
A new service which allows people to register their interest in participating in dementia research and be matched to suitable studies.